ArticleBrain pathology (Zurich, Switzerland)2019
Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients.
Article in Brain pathology (Zurich, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- A review of solitary fibrous tumor/hemangiopericytoma tumor and a comparison of risk factors for recurrence, metastases, and death among patients with spinal and intracranial tumors.Neurosurgical review · 2021Pooled it
- Solitary Fibrous Tumours in the Central Nervous System and Their Clinical Mimickers: A Case Series.Cureus · 2026Article
- Article
- Solitary fibrous tumor: an updated review.Journal of pathology and translational medicine · 2026Article
- Rapid progression of recurrent intracranial solitary fibrous tumor following a previously reported TERT-wild-type primary tumor: a case report.Frontiers in oncology · 2026Article
- Late recurrence and histological progression of a cervical intradural extramedullary solitary fibrous tumor after gross total resection: a case report.Frontiers in oncology · 2026Article
- Meningeal Solitary Fibrous Tumor: A Cytological Report With Emphasis on the Usefulness of Immunocytochemical Analysis for STAT6.Diagnostic cytopathology · 2025Article
- The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors.Acta neuropathologica communications · 2025Article
- A clinical investigation of extracranial metastases in 17 cases of intracranial solitary fibrous tumors.World journal of surgical oncology · 2025Article
- Mesenchymal Nonmeningothelial Tumors of the CNS: Evolving Molecular Landscape and Implications for Neuroradiologists.AJNR. American journal of neuroradiology · 2025Review
- Solitary fibrous tumor in the pineal region: A series of 5 cases and literature review.Journal of neuropathology and experimental neurology · 2025Review
- The Clinical Application of Dynamic Contrast-Enhanced MRI in Canine Masses of Mesenchymal and Epithelial Origin: A Preliminary Case Series.Veterinary sciences · 2024Article
- NAB2::STAT6 fusions and genome-wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors.Brain pathology (Zurich, Switzerland) · 2024Article
- Solitary fibrous tumor of the brain: A report of 3 cases.Oncology letters · 2024Article
- Descriptive epidemiology of 399 histologically confirmed newly diagnosed meningeal solitary fibrous tumours and haemangiopericytomas in France: 2006-2015.Acta neurochirurgica · 2024Article
- Efficacy and toxicity of photon, proton, and carbon ion radiotherapy in the treatment of intracranial solitary fibrous tumor/hemangiopericytoma.Radiation oncology (London, England) · 2024Article
- The role of tumor parenchyma and brain cortex signal intensity ratio in differentiating solitary fibrous tumors and meningiomas.Discover oncology · 2024Article
- Surgical Management of Craniospinal Axis Solitary Fibrous Tumors: A Single-Institution Case Series and Comprehensive Review of the Literature.Neurosurgery · 2024Review
- Solitary Fibrous Tumor of the Central Nervous System: A Report of Two Cases with Emphasis on Diagnostic Pitfalls.Case reports in pathology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The finding that meningeal solitary fibrous tumors (SFTs) and meningeal hemangiopericytomas (HPCs) are both characterized by NAB2-STAT6 gene fusion has pushed their inclusion in the WHO 2016 Classification of tumors of the central nervous system (CNS) as different manifestations of the same entity. Given that the clinical behavior of the CNS SFT/HPC spectrum ranges from benign to malignant, it is presently unclear whether the grading criteria are still adequate. Here, we present the results of a study that analyzed the prognostic value of an updated version of the Marseille Grading System (MGS) in a retrospectively assembled cohort of 132 primary meningeal SFTs/HPCs with nuclear overexpression of STAT6. The median patient follow-up was 64 months (range 4-274 months); 73 cases (55%) were MGS I, 50 cases (38%) MGS II and 9 cases (7%) were MGS III. Progression-free survival (PFS) and disease-specific survival (DSS) were investigated using univariate analysis: the prognostic factors for PFS included MGS, extent of surgery, radiotherapy, chemotherapy and mitotic activity ≥5/10 high-power field (HPF). Moreover, MGS, radiotherapy, mitotic activity ≥5/10 HPF, and necrosis were the prognostic factors measured for DSS. In multivariate analysis, extent of surgery, mitotic activity ≥5/10 HPF, MGS I and MGS III were the independent prognostic factors measured for PFS while necrosis, MGS III and radiotherapy were the independent prognostic factors for DSS. In conclusion, our results show that assessing the malignancy risk of SFT/HPC should not rely on one single criterion like mitotic activity. Therefore, MGS is useful as it combines the value of different criteria. In particular, the combination of a high mitotic activity and necrosis (MGS III) indicates a particularly poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.